Phase II study of olaparib plus durvalumab with or without bevacizumab (MEDIOLA): Final analysis of overall survival in patients with non-germline BRCA-mutated platinum-sensitive relapsed ovarian cancer

被引:19
作者
Banerjee, S. [1 ,2 ]
Imbimbo, M. [3 ]
Roxburgh, P. [4 ,5 ]
Kim, J-W. [6 ]
Kim, M. H. [7 ]
Plummer, R. [8 ,9 ]
Stemmer, S. [10 ]
You, B. [11 ]
Ferguson, M. [12 ]
Penson, R. T. [13 ]
O'Malley, D. [14 ]
Meyer, K. [15 ]
Gao, H. [16 ]
Angell, H. [17 ]
Nunes, A. Tablante [18 ]
Domchek, S. [19 ]
Drew, Y. [8 ,9 ]
机构
[1] Royal Marsden NHS Fdn Trust, Gynaecol Unit, London, England
[2] Inst Canc Res, London, England
[3] Univ Lausanne, Lausanne Univ Hosp, Dept Oncol, Lausanne, Switzerland
[4] Univ Glasgow, Med Oncol, Beatson West Scotland Canc Ctr, Glasgow, Scotland
[5] Univ Glasgow, Inst Canc Sci, Glasgow, Scotland
[6] Seoul Natl Univ Hosp, Dept Obstet & Gynaecol, Seoul, South Korea
[7] Yonsei Univ, Div Med Oncol, Dept Internal Med, Yonsei Canc Ctr,Coll Med, Seoul, South Korea
[8] Newcastle Upon Tyne Hosp NHS Fdn Trust, Northern Ctr Canc Care, Translat & Clin Res Inst, Newcastle Upon Tyne, Tyne & Wear, England
[9] Newcastle Univ, Newcastle Upon Tyne, Tyne & Wear, England
[10] Rabin Med Ctr, Davidoff Ctr, Beilinson Campus, Petah Tiqwa, Israel
[11] Univ Claude Bernard Lyon 1, Univ Lyon, Inst Cancerol Hosp Civils Lyon IC HCL, Serv Oncol Med,CITOHL,GINECO, Pierre Benite, France
[12] NHS Tayside, Ninewells Hosp, Dept Oncol, Dundee, Scotland
[13] Massachusetts Gen Hosp, Div Haematol Oncol, Boston, MA USA
[14] Ohio State Univ, Div Gynaecol Oncol, James Comprehens Canc Ctr, Columbus, OH USA
[15] AstraZeneca, Late Dev Oncol, Oncol R&D, Gaithersburg, MD USA
[16] AstraZeneca, Late Oncol Stat, Oncol R&D, Cambridge, England
[17] AstraZeneca, Translat Med, Oncol R&D, Cambridge, England
[18] AstraZeneca, Immuno Oncol, Late Phase R&D, Gaithersburg, MD USA
[19] Univ Penn, Basser Ctr BRCA, Philadelphia, PA USA
关键词
D O I
10.1016/j.annonc.2022.07.657
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
529MO
引用
收藏
页码:S788 / S789
页数:2
相关论文
empty
未找到相关数据